
Beacon is working with our client partner to raise awareness about low-lying lids (acquired blepharoptosis) and increase diagnosis and treatment with the first and only FDA-approved prescription eyedrop. This campaign speaks to both HCPs and patients through unbranded and branded channels to:
See how our launch of the first and only agent for a common yet under-recognized eyelid disorder motivated HCP-patient dialogue and diagnosis while creating a new standard for first-line treatment.